Author: Bill Snyder
Personalized Structural Biology aids cancer treatment decisions
Apr. 8, 2021—Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.
Health care quality expert Berwick set for Discovery Lecture
Apr. 7, 2021—Donald Berwick, MD, MPP, one of the nation’s leading authorities on health care quality and improvement, will deliver the next web-based Discovery Lecture on Thursday, April 15, at 4 p.m. via Zoom.
U.S. government reserves supply of COVID-19 antibody cocktail discovered at VUMC
Apr. 6, 2021—The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced.
Investigational vaccine to be tested against COVID-19 variant
Apr. 2, 2021—Vanderbilt University Medical Center is participating in a national phase 1 clinical trial in healthy adults of an investigational vaccine against the B.1.351 variant of the COVID-19 virus that was first identified in South Africa.
Novel way to neutralize Rift Valley Fever Virus
Apr. 1, 2021—The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.
Study shows new COVID target could improve vaccines
Apr. 1, 2021—Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus.
Physician-scientists Aliyu, Tindle elected to ASCI
Mar. 31, 2021—Vanderbilt’s Muktar Aliyu, MBBS, MPH, DrPH, and Hilary Tindle, MD, MPH, will be inducted this year into the American Society for Clinical Investigation (ASCI), an elite honor society of physician-scientists from the upper ranks of academic medicine and industry.
Study to assess allergic reactions to COVID vaccines
Mar. 18, 2021—Vanderbilt University Medical Center is recruiting volunteers for a randomized controlled phase 2 clinical trial to help determine the prevalence of systemic allergic reactions (SARS) to the two-dose COVID-19 mRNA vaccines made by Pfizer-BioNTech and Moderna.
‘Friendly’ bacteria may impact COVID severity
Mar. 11, 2021—The U.S. Centers for Disease Control and Prevention (CDC) has awarded Vanderbilt University Medical Center a two-year, $3.7-million contract to determine genetic and bacterial factors that may increase the risk for severe illness and death from COVID-19.
Discovery Lecture to feature geriatric medicine expert Cassel
Mar. 11, 2021—Christine Cassel, MD, a leading expert in geriatric medicine, medical ethics and the quality of care, will deliver the next web-based Discovery Lecture on Thursday, March 25, at 4 p.m. via Zoom.
Monoclonal antibody “cocktail” blocks COVID-19 variants: study
Mar. 4, 2021—A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published today in the journal Nature Medicine.
Chikungunya antibody identified at VUMC moves forward
Mar. 4, 2021—Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.
